

## Curriculum Vitae

**Samira FAFI-KREMER**



**Date of Birth** March 15, 1972, Meknes, Morocco,

**Position**

- Professor of Medicine – Attending Physician (PU-PH), Classe Exceptionnelle, Strasbourg University and Strasbourg University Hospitals, France
- Head of the Department of Medical Virology, Strasbourg University Hospitals
- Coordinator of Microbiology Department (PTM)
- Research Group Leader, Inserm Unit U1109, Labex TRANSPLANTE, Strasbourg University

**Distinction** Knight of the French National Order of the Legion of Honour

### Appointments and Positions – Clinical

2018- Coordinator of Microbiology Department (PTM), Strasbourg University Hospitals  
2015- Head of the Department of Medical Virology, Strasbourg University Hospitals  
2013- Professor of Medicine– Attending Physician (PU-PH), Department of Medical Virology, Pole of Biology, Strasbourg University Hospitals, France  
2011-2015 Head of the Unit of Molecular Microbiology, Strasbourg University Hospitals, France  
2007-2013 Assistant Professor of Medicine-Attending Physician (MCU-PH), Department of Medical Virology, Pole of Biology, University Hospitals, Strasbourg  
2005-2007 Resident (AHU), Department of Medical Virology, Pole of Biology, Strasbourg University Hospitals, France.  
2001-2005 Resident (AHU), Department of Medical Virology, University Hospitals, Grenoble  
1997-2001 Intern in “Pharmacie Spécialisée”, Faculty of Pharmacy, Joseph Fourier University, Grenoble, France

### Appointments and Positions – Research

2021 Member of the Committee for Scientific Research, Strasbourg University Hospitals, France.  
2014 Head of Research Team Inserm Unit U1109, Labex TRANSPLANTE, Strasbourg University.  
2011-2013 Coordinator of Translational Medicine Platform, Inserm Virology Unit U1110, Strasbourg University  
2010- Research group leader, Inserm Virology Unit U1110, Labex “HEPSYS”, Strasbourg University  
2006-2009 Postdoc in Inserm Unit 748, “Virus-host interactions and liver disease”, Strasbourg University  
2001-2005 Doctoral student, Joseph Fourier University, Grenoble, France.

### Education

2014 Management Training, **HEC Executive Education, HEC, Jouy-en Josas.**  
2009 Habilitation (HDR), **Faculty of Medicine, Strasbourg University, France**  
2005 University Thesis, Speciality « Bio-Technologie Santé et Management », **Joseph Fourier University, Grenoble.**  
2004 Diplôme Universitaire de Pédagogie Médicale, **Faculté de Médecine, Grenoble**  
2001 Doctor of Pharmacy, DES Pharmacie Spécialisée, DES Biologie Médicale, **Joseph Fourier University, Grenoble, France**  
2000 Master research degree “Génie Biologique et Médical », **Joseph Fourier University, Grenoble, France**  
1990-2001 Pharmaceutical School, **University of Grenoble, France**  
1989-1990 Faculty of Biology, **Meknes, Morocco.**  
1989 Baccalauréat Section Sciences Expérimentales Bilingues, Morocco.

## Teaching

### Lectures and seminars in basic and medical virology:

- 2<sup>nd</sup> and 3<sup>rd</sup> cycle of Medical studies\_ **Strasbourg Medical School, Strasbourg, France**
- 1<sup>st</sup> cycle of Medical studies\_ **Medical school of Jiaotong, Shanghai, China**
- Master and PhD programs\_ **Strasbourg University, France**
- Postgraduate education medical doctors\_ **Strasbourg University Hospitals, France**

### Research supervision

- PhD students (7)
- Master 1 (15 students) et Master 2 recherche (13 students)

## Main publications 2020-2022

1. **Fafi-Kremer S**, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, Staropoli I, Anna F, Souque P, Fernandes-Pellerin S, Jolly N, Renaudat C, Ungeheuer MN, Schmidt-Mutter C, Collongues N, Bolle A, Velay A, Lefebvre N, Mielcarek M, Meyer N, Rey D, Charneau P, Hoen B, De Seze J, Schwartz O, Fontanet A. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. *EBioMedicine*. 2020 (IF: 11,20)
2. Benotmane I, Gautier-Vargas G, Wendling MJ, Perrin P, Velay A, Bassand X, Bedo D, Baldacini C, Sagnard M, Bozman DF, Della-Chiesa M, Solis M, Gallais F, Cognard N, Olagne J, Delagrèverie H, Gontard L, Panaget B, Marx D, Heibel F, Braun-Parvez L, Moulin B, Caillard S, **Fafi-Kremer S**. In-depth virological assessment of kidney transplant recipients with COVID-19. *Am J Transplant*. 2020;20:3162-3172. (IF: 9,39)
3. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, **Fafi-Kremer S**, Ohana M, Anheim M, Meziani F. Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med*. 2020 4;382:2268-2270. (IF: 74,69)
4. Sentilhes L, De Marcillac F, Jouffrieau C, Kuhn P, Thuet V, Hansmann Y, Ruch Y, **Fafi-Kremer S**, Deruelle P. Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. *Am J Obstet Gynecol*. 2020;223:e1-914.e15. (IF: 8,66)
5. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilia J, Candon S, **Fafi-Kremer S**. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. *Emerg Infect Dis*. 2021 Jan;27(1):113–21. (IF: 6,26)
6. Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, Wendling MJ, Meyer N, Planchais C, Rey D, Mouquet H, Reix N, Glady L, Hansmann Y, Bruel T, De Sèze J, Fontanet A, Gonzalez M, Schwartz O, **Fafi-Kremer S**. Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2. *J Infect Dis*. 2021 Mar 7:jjab127. (IF: 7,76)
7. Caillard S, Benotmane I, Gautier Vargas G, Perrin P, **Fafi-Kremer S**. SARS-CoV-2 viral dynamics in immunocompromised patients. *Am J Transplant*. 2021 Apr;21(4):1667-1669. (IF: 9,39)
8. Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, Mengin A, Gras A, Vidailhet P, Arnould-Michel R, Bibi-Triki S, Carapito R, Trouillet-Assant S, Perret M, Belot A, Bahram S, Arnaud L, Gottenberg JE, **Fafi-Kremer S**, Sibilia J. Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. *Infect Dis Ther*. 2021 Sep;10(3):1747-1763. (IF: 5,32)
9. Benotmane I, Risch S, Doderer-Lang C, Caillard S, **Fafi-Kremer S**. Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19. *Am J Transplant*. 2021 Aug;21(8):2871-2875. doi: 10.1111/ajt.16636. (IF: 9,39)
10. Benotmane I, Gautier-Vargas G, Gallais F, Gantner P, Cognard N, Olagne J, Velay A, Heibel F, Braun-Parvez L, Martzloff J, Perrin P, Moulin B, **Fafi-Kremer S**, Caillard S. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. *Am J Transplant*. 2021 Jul 13. (IF: 9,39)
11. Martinot M, Carnein S, Kempf C, Gantner P, Gallais F, **Fafi-Kremer S**. Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination. *Clin Microbiol Infect*. 2021 Jul 7:S1198-743X(21)00369-4. (IF: 7,12)
12. Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C, Buchrieser J, Rajah MM, Bishop E, Albert M, Donati F, Prot M, Behillil S, Enouf V, Maquart M, Smati-Lafarge M, Varon E, Schortgen F, Yahyaoui L, Gonzalez M, De Sèze J, Péré H, Veyer D, Sève A, Simon-Lorière E, **Fafi-Kremer S**, Stefic K, Mouquet H, Hocqueloux L, van der Werf S, Prazuck T, Schwartz O. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat Med*. 2021;27:917-924. (IF: 36,13)
13. Lersy F, Benotmane I, Helms J, Collange O, Schenck M, Brisset JC, Chammas A, Willaume T, Lefebvre N, Solis M, Hansmann Y, Fabacher T, Caillard S, Mertes PM, Pottecher J, Schneider F, Meziani F, **Fafi-Kremer S**, Kremer S. Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. *J Infect Dis*. 2021 Feb 24;223(4):600-609. (IF: 7,76)
14. Benotmane I, Gautier Vargas G, Velay A, Wendling MJ, Perrin P, **Fafi-Kremer S**, Caillard S. Persistence of SARS-CoV-2 antibodies in kidney transplant recipients. *Am J Transplant*. 2021 Jun;21(6):2307-2310. (IF: 9,39)
15. Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L, Martzloff J, Perrin P, Moulin B, **Fafi-Kremer S**, Caillard S. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. *Kidney Int*. 2021 Jun;99(6):1498-1500. (IF: 18,99)
16. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassiss-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, **Fafi-Kremer S**, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*. 2021 Aug;596(7871):276-280. (IF: 42,78)
17. Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, **Fafi-Kremer S**, Caillard S. Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. *JAMA*. 2021 Jul 23. (IF: 45,54)
18. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, Bayer S, Solis M, Laugel E, Reix N, Schneider A, Glady L, Panaget B, Collongues N, Partisani ML, Lessinger JM, Fontanet A, Rey D, Hansmann Y, Kling-Pillitteri L, Schwartz O, De Sèze J, Meyer N, Gonzalez M, Schmidt-Mutter C, **Fafi-Kremer S**. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. *EBioMedicine*, 2021, in press (IF: 11,20)
19. Gallais F, Renaud-Picard B, Solis M, Laugel E, Soulier E, Caillard S, Kessler, R, **Fafi-Kremer S**. Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients. *J Heart Lung Transplant*. 2022 Oct;41(10):1429-1439 (IF: 13,56)